AstraZeneca announces Stage III study outcomes of naloxegol in sufferers with non-cancer pain AstraZeneca today announced the outcomes of a Stage III long-term security and tolerability research of the once-daily 25mg dosage of naloxegol, in individuals with non-cancer discomfort and opioid-induced constipation . Naloxegol can be an investigational peripherally-performing mu-opioid receptor antagonist , which includes been studied in OIC in adult individuals with chronic non-cancer discomfort, a common condition due to prescription opioid pain medications generic cialis online . Data were provided at the American University of Gastroenterology 2013 Annual Scientific Getting together with in NORTH PARK, California.

Resource: Kligler B, Homel P, Blank AE, et al. Randomized trial of the result of an integrative medication approach to the administration of asthma in adults on disease-related standard of living and pulmonary function. Choice Therapies 2011; 17:10-15 About the writer:Dr. Randall Neustaedter, OMD, has practiced and trained holistic medicine for a lot more than thirty years in the SAN FRANCISCO BAY AREA Bay area, specializing in child healthcare. He is an authorized doctor and acupuncturist of Chinese medicine, writer of The Holistic Baby Guidebook, Child Health Information and The Vaccine Instruction. Visit his website, to join up for a free of charge newsletter with pediatric specialty content and follow him on Facebook, in Dr.

Other articles from "drugs":

Random articles